

The Journal of Rheumatology

VOLUME 36: NO. 8

jrheum.org

AUGUST 2009

Editorials

- Anti-Tumor Necrosis Factor Agents Are Mostly Used in Patients with Established Rheumatoid Arthritis Compared to Early Disease — A Reflection of Adequate Clinical Practice
B. Haraoui 1561

- Quantitative Clinical Rheumatology: Why Is a Test for Anti-CCP Antibodies Included in Most Routine Care for Rheumatoid Arthritis While a HAQ/MDHAQ Remains Largely a Research Tool?
T. Pincus, Y. Yazici, M.J. Bergman 1563

- Anti-Cyclic Citrullinated Peptide Antibody versus HAQ/MDHAQ: Comparing Apples and Oranges?
V. Bykerk 1565

- The Many Myths of Erythrocyte Sedimentation Rate and C-Reactive Protein
F. Wolfe 1568

- Bisphosphonates in Patients with Glucocorticoids: Time for Implementation
W.F. Lems 1570

- Towards a New Clinico-Immunopathological Classification of Juvenile Inflammatory Arthritis
D. McGonagle, M. Benjamin 1573

Articles

- The TNF- α -blocking Agent Infliximab Inhibits IL-1 β and IL-6 Gene Expression in Human Osteoblastic Cells
E. Musacchio, C. Valvason, C. Botsios, et al 1575

- Expression and Function of Histone Deacetylases in RA Synovial Fibroblasts
M. Horiuchi, A. Morinobu, T. Chin, Y. Sakai, M. Kurosaka, S. Kumagai 1580

- Lack of Association with RA of Selected Polymorphisms in 4 Candidate Genes: *CFH*, *CD209*, *Eotaxin-3*, and *MHC2TA*
R. Dieguez-Gonzalez, S. Akar, M. Calaza, et al 1590

- Declines in ESR in Patients with RA Over the Second Half of the 20th Century
B. Abelson, T. Sokka, T. Pincus 1596

- A Followup Study of Asymptomatic Carriers of *P. jiroveci* During Immunosuppressive Therapy for RA
S. Mori, I. Cho, M. Sugimoto 1600

- Which Measure of Inflammation to Use? A Comparison of ESR and CRP Measurements from Randomized Clinical Trials of Golimumab in RA
C.S. Crowson, M.U. Rahman, E.L. Matteson 1606

- Utilization Trends of TNF Inhibitors Among Patients with RA in a US Observational Cohort Study
S.J. Lee, H. Chang, Y. Yazici, J.D. Greenberg, J.M. Kremer, A. Kavanaugh 1611

- Severe Disease Activity and Complications of Immunosuppressive Therapy: A Challenge for Acute Hospital-based Rehabilitation in Rheumatology
K. Kujath, K.-G.A. Hermann, K. Mathiske-Schmidt, et al 1618

- Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome
C.P. Mavragani, F.N. Skopouli, H.M. Moutsopoulos 1626

- Evidence for Genetic Association and Interaction Between the *TYK2* and *IRF5* Genes in SLE
A. Hellquist, T.M. Järvinen, S. Koskenmies, et al 1631

- Changes in Lipid Profile Between Flare and Remission of Patients with SLE: A Prospective Study
M. Urquiza-Padilla, E. Balada, P. Chacon, E. Hermosilla Pérez, M. Vilardell-Tarrés, J. Ordi-Ros 1639

- High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with SLE
E.K. Li, L.S. Tam, J.F. Griffith, et al 1646

- Improvement of Severe SSc-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with IV Cyclophosphamide
S.W. Schulz, M. O'Brien, M. Maqsood, N. Sandorfi, F. Del Galdo, S.A. Jimenez 1653

- Elevated Circulating TWEAK Levels in SSc: Association with Lower Frequency of Pulmonary Fibrosis
K. Yanaba, A. Yoshizaki, E. Muroi, et al 1657

- Diagnosis of Raynaud's Phenomenon by 99m Tc-HDP Digital Blood Flow Scintigraphy After One-hand Chilling
S.-R. Kwon, M.-J. Lim, S.-G. Park, I.-Y. Hyun, W. Park 1663

- Clinical and Genetic Features of Familial Mediterranean Fever in Japan
A. Tsuchiya-Suzuki, M. Yazaki, A. Nakamura, et al 1671

Contents continued opposite inside back cover ...

A Clinical Criterion to Exclude the Hyperimmunoglobulin D Syndrome (Mild Mevalonate Kinase Deficiency) in Patients with Recurrent Fever <i>O. Steichen, J. van der Hilst, A. Simon, L. Cuisset, G. Grateau</i>	1677
Absence of <i>M. tuberculosis</i> in Arterial Lesions from Patients with Takayasu's Arteritis <i>L. Arnaud, E. Cambau, I. Brocheriou, et al</i>	1682
The Presence of Limited Joint Mobility Is Significantly Associated with Multiple Digit Involvement by Stenosing Flexor Tenosynovitis in Diabetics <i>M. Kameyama, S. Meguro, O. Funae, Y. Atsumi, H. Ikegami</i>	1686
Serum Uric Acid Is Independently Associated with Metabolic Syndrome in Subjects with and without a Low Estimated GFR <i>L-C. See, C-F. Kuo, F-H. Chuang, et al</i>	1691
Impact of a Rheumatology Consultation Service on the Diagnostic Accuracy and Management of Gout in Hospitalized Patients <i>C. Barber, K. Thompson, J.G. Hanly</i>	1699
Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial <i>S.A. Stoch, K.G. Saag, M. Greenwald, et al</i>	1705
Sensitivity and Specificity of Ultrasonography in Early Diagnosis of Metatarsal Bone Stress Fractures: A Pilot Study of 37 Patients <i>F. Banal, F. Gandjbakhch, V. Foltz, et al</i>	1715
Increased Frequency of GI Symptoms in Patients with Fibromyalgia and Associated Factors: A Comparative Study <i>Ö.N. Pamuk, H. Ümit, O. Harmandar</i>	1720
Pediatric Rheumatology	
Ankle Disease in JIA: Ultrasound Findings in Clinically Swollen Ankles <i>M.E. Rooney, C. McAllister, J.F.T. Burns</i>	1725
Th1 and Th17 Predominance in the Enthesitis-related Arthritis Form of JIA <i>A. Mahendra, R. Misra, A. Aggarwal</i>	1730
Biomarkers of Chronic Uveitis in JIA: Predictive Value of Antihistone Antibodies and Antinuclear Antibodies <i>E.B. Nordal, N.T. Songstad, L. Berntson, T. Moen, B. Straume, M. Rygg</i>	1737
Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases <i>A. Brucato, C. Grava, M. Bortolati, et al</i>	1744
Cartilage Oligomeric Matrix Protein in Patients with JIA: Relation to Growth and Disease Activity <i>B. Bjørnhart, A. Juul, S. Nielsen, M. Zak, P. Svenningsen, K. Müller</i>	1749
Surfing for JIA: Perspectives on Quality and Content of Information on the Internet <i>J.N. Stinson, L. Tucker, A. Huber, et al</i>	1755
Images in Rheumatology	
The Radiographic Scars of Glucocorticoid Treatment in SLE <i>J.W. Maynard, A.C. Gelber</i>	1763

OMERACT 9: International Consensus Conference on Outcome Measures in Rheumatology, Kananaskis Village, Alberta, Canada, May 27–31, 2008

Introduction	
<i>P. Tugwell, M. Boers, V. Strand, L.S. Simon, P. Brooks</i>	1767
Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in RA: A Systematic Literature Search on 5 Candidate Biomarkers	
<i>S.W. Syversen, R. Landewé, D. van der Heijde, et al</i>	1769
Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in RA, PsA, and Spondyloarthritis: The OMERACT 9 v2 Criteria	
<i>W.P. Maksymowich, R. Landewé, P-P. Tak, et al</i>	1785
Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in RA, PsA, and AS, and Recommendations for Study Design	
<i>W.P. Maksymowich, O. Fitzgerald, G.A. Wells, et al</i>	1792
Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in RA Clinical Trials: Consistency Across Centers	
<i>B. Bresnihan, E. Pontifex, R.M. Thurlings, et al</i>	1800
The OMERACT MRI Inflammatory Arthritis Group: Advances and Future Research Priorities	
<i>P.G. Conaghan, P. Bird, F. McQueen, et al</i>	1803
Reducing Invasiveness, Duration, and Cost of MRI in RA by Omitting IV Contrast Injection — Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?	
<i>M. Østergaard, P.G. Conaghan, P. O'Connor, et al</i>	1806
Testing an OMERACT MRI Scoring System for Peripheral PsA in Cross-sectional and Longitudinal Settings	
<i>F. McQueen, M. Lassere, A. Duer-Jensen, et al</i>	1811
The OMERACT PsA MRI Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands	
<i>M. Østergaard, F. McQueen, C. Wiell, et al</i>	1816
Multiple Computer-based Methods of Measuring JSW Can Discriminate Between Treatment Arms in the COBRA Trial — Update of an Ongoing OMERACT Project	
<i>J.T. Sharp, J. Angwin, M. Boers, et al</i>	1825
The OMERACT Ultrasound Task Force — Advances and Priorities	
<i>M-A. D'Agostino, P.G. Conaghan, E. Naredo, et al</i>	1829
Correspondence	
Missing the Obvious	
<i>D.M. Nuenninghoff</i>	1833
Reply	
<i>P. Claudepierre</i>	1833

Limitations of ANA Tests (HEp-2) Are Overcome with the Autoimmune Target Test (IT-1) in SLE <i>L-H. Jearn, D-A. Kim, T-Y. Kim</i> 1833	Assessing Mitral Valve Stenosis by Real-time 3-Dimensional Echocardiography in SLE: A Look Inside the Heart <i>S.C. Plastiras, C.A. Pamboucas, G.E. Tzelepis, S.T. Toumanidis</i> 1843
Reply <i>T. Skogh, A.A. Bengtsson, C. Dahle, et al.</i> 1834	Mimics of Vasculitis: Vascular Ehlers-Danlos Syndrome Masquerading as Polyarteritis Nodosa <i>R.A. Badawi, L.H. Brent, D.E. Feinstein</i> 1845
Letters	Atypical Symptom of Ehlers-Danlos Syndrome Impeding Diagnosis: Feeling of Spinal Instability <i>R. Gasik, T. Styczynski</i> 1847
Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy <i>A.N. Lau, J.D. Adachi</i> 1835	Painful Lower Extremities Related to Diaphyseal Dysplasia: Genetic Diagnosis and Treatment <i>S.L.E. Ribeiro, E.L. Guedes, V.M.G. Prazeres, E.J.G. de Freitas, A.R.C. Fernandes</i> 1848
Interaction of Human Recombinant TNF-Related Apoptosis-Inducing Ligand and Osteoprotegerin Could Contribute to Enhancement of the Erosive Processes Induced by Human Synovial Cells <i>P. Narducci, R. Bareggi, V. Nicolin</i> 1837	Corrections
Thymoglobulin and Cyclophosphamide as Treatment for Diffuse Cutaneous Systemic Sclerosis <i>L.A. Holmberg, D.E. Furst, P.A. McSweeney, R.A. Nash</i> 1839	Assessment and Management of Rheumatoid Arthritis <i>B. Haraoui</i> 1851
Steroid Injection Performed with Fluoroscopy for Treatment of a Discal Cyst <i>T. Dumay-Levesque, A-C. Souteyrand, J-L. Michel</i> 1841	Serum Urate During Acute Gout <i>N. Schlesinger, J.M. Norquist, D.J. Watson</i> 1851
	Meetings in Rheumatology